wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36245461-1417C67F-EBF6-4ACB-ADE2-9E142C1FCAD4
Q36245461-1417C67F-EBF6-4ACB-ADE2-9E142C1FCAD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36245461-1417C67F-EBF6-4ACB-ADE2-9E142C1FCAD4
Current approaches to the management of Her2-negative metastatic breast cancer.
P2860
Q36245461-1417C67F-EBF6-4ACB-ADE2-9E142C1FCAD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36245461-1417C67F-EBF6-4ACB-ADE2-9E142C1FCAD4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
eb82bcdc4213b00dc1f27b78c48da8b04445eecc
P2860
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.